The Antiviral Gap in U.S. Force Protection
A Bundibugyo outbreak and a shelved drug candidate reveal why biodefense countermeasures must be stockpiled before the crisis, not during it.
By The Defense Desk
When the Bundibugyo Ebola strain resurfaced, there was no licensed vaccine and no approved therapeutic waiting for it. [1] That gap is not a public health failure — it is a force protection problem.
The U.S. Army Medical Research Institute of Infectious Diseases ran Biosafety Level 4 preclinical trials on rintatolimod, AIM ImmunoTech's drug Ampligen, as a potential Ebola prophylactic. The peer-reviewed journal Antiviral Research reported 100% survival in one rintatolimod-treated cohort in a lethal mouse model, compared with 100% mortality in controls. [1] The compound has not advanced to an FDA-approved countermeasure.
The COVID-19 outbreak aboard the USS Theodore Roosevelt infected approximately 1,200 sailors and disrupted operations of one of America's most important military assets. [1] Government-funded antiviral research on SARS-related coronaviruses existed before the pandemic — conducted at the Institute for Antiviral Research at Utah State University — but never reached an approved, stockpiled countermeasure before the next crisis arrived. [1]
The pattern is consistent: science advances to proof-of-concept, procurement cycles stall, and the threat arrives before the shelf is stocked. Readiness built after exposure is not readiness at all.
Biological threats move faster than policy, procurement, budgeting, interagency coordination, government-use approvals and stockpile decisions. [1] Broad-spectrum prophylactic antiviral countermeasures — evaluated through FDA-regulated pathways, manufactured, and stockpiled against priority threats — belong in the same force protection planning as diagnostics, detection systems, and protective equipment. [1]
The next novel pathogen will not pause for a budget cycle. Promising antiviral platforms need to clear regulatory pathways and reach the stockpile while there is still time to use them.
if promising broad-spectrum antiviral prophylactics are not advanced through appropriate government-supported and FDA-regulated evaluation pathways, they can remain research findings on the shelf rather than tools available for emergency planning.Thomas K. Equels